ACLY and prostate cancer: Their research results include that miR-22 effectively inhibits tumor growth and metastasis by targeting and inhibiting ATP citrate lyase (ACLY), providing potential therapeutic benefits for osteosarcoma, prostate cancer, cervical cancer, and lung cancer (56).